Drug Digest: Automation in Biopharma and the Impact on Workflows

In this exclusive Drug Digest video interview, Meg Rivers and Feliza Mirasol, Pharmaceutical Technology editors, discuss the benefits of automating entire workflows in analytics (laboratories) versus automating only specific pieces of equipment or only certain processes. What influence or impact would this have on workflows further downstream, such as clinical or commercial manufacturing?

They discuss additional topics, including:

• Additional automation approaches and how modular approaches fit into this
• Automation opportunities in pharma (i.e., small molecule) vs. biopharma (i.e., large molecule)
• Whether the level of adoption of automation differs in the industry between pharma and biopharma
• How this trend toward automation in laboratory workflows impacts clinical and commercial drug development and manufacturing
  

Interview featuring

Nick Pattinson is the head of product at Automata, a London-based biotech company providing robotic automation solutions to the life sciences industry. He is a trained mechanical engineer and studied at Oxford University. Pattinson joined Automata to help make real, tangible change and help unlock the potential of scientists through automation in laboratories.

Sponsors

This episode of Drug Digest is sponsored by:

• Adare Pharma Solutions
• Aizon
• FESTO
• L.B. Bohle
• Veltek Associates

About Drug Digest

Drug Digest is a tech talk video series with the Pharmaceutical Technology editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products.

Upcoming episodes

• January 2023: 2023 Trends—QMM